Belrestotug - iTeos Therapeutics
Alternative Names: EOS 884448; EOS-448; GSK-4428859; GSK-4428859A; TIGIT antagonist monoclonal antibody - iTeos TherapeuticsLatest Information Update: 05 Jul 2024
At a glance
- Originator iTeos Therapeutics
- Developer GSK; iTeos Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Squamous cell cancer
- Phase I/II Haematological malignancies; Multiple myeloma; Solid tumours
Most Recent Events
- 10 Jun 2024 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (IV) (NCT06472076)
- 10 May 2024 Interim efficacy and adverse events data from a phase II trial in Non small cell lung cancer released by iTeos Therapeutics
- 10 May 2024 iTeos Therapeutics completes enrolment in its phase I/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in US, Belgium, France, Italy, Spain and United Kingdom (IV) (NCT05060432)